Core Viewpoint - HCM's stock opened up by 2.08% on August 15, with a market capitalization of $2.826 billion, despite a year-over-year revenue decline of 9.16% to $27.8 million, while net profit surged by 1663.32% to $455 million as of June 30, 2025 [1][1][1] Group 1: Financial Performance - As of June 30, 2025, HCM reported total revenue of $27.8 million, a decrease of 9.16% year-over-year [1] - The company achieved a net profit of $455 million, reflecting a significant increase of 1663.32% compared to the previous year [1] Group 2: Company Overview - HCM is recognized as one of China's first innovative pharmaceutical research and development companies focused on the global market [1] - Over the past 20 years, the company has established a comprehensive and integrated R&D innovation platform with world-class discovery and development capabilities [1] - HCM has successfully launched three self-discovered anti-tumor candidate drugs in China, with the first drug also approved in the United States [1] - The company has built a profitable commercial platform in China for the production, marketing, and distribution of its innovative oncology drugs, prescription drugs, and consumer healthcare products [1] - HCM is listed on the NASDAQ Global Select Market, Hong Kong Stock Exchange, and London Stock Exchange's AIM market [1]
和黄医药(US ADR)上涨2.08%，报16.2美元/股，总市值28.26亿美元